SLS
NASDAQ · Biotechnology
Sellas Life Sciences Group I
$9.03
-0.11 (-1.20%)
Analyst Consensus
Strong Buy
6
Analysts
Moderate
Coverage
Price Target
Analyst Price Target
+275.4% upside
Low Target
$25.20
Average Target
$33.90
High Target
$43.49
Current Price
$9.03
Current
$9.03
$9.03
Target
$33.90
$33.90
$25.20
$33.90 avg
$43.49
Scenario Analysis
Bear Case
$25.20
179.1%
Low target
Base Case
$33.90
+275.4%
Avg target
Bull Case
$43.49
+381.6%
High target
Risk/Reward
2.1x
Favorable
Price in Context
52-Week High
$15.88
-43.1% from high
52-Week Low
$1.39
+549.6% from low
Target vs 52W High
$33.90
+113.5% vs high
Next Earnings Report
Nov 10, 2026
3d
until earnings
EPS Est: $-0.05
Earnings in 3 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 39 | 82% | $257.58 | -10.6% |
| AMGN | Hold | 42 | 43% | $190.87 | -58.5% |
| GILD | Strong Buy | 37 | 81% | $362.68 | +116.4% |
| VRTX | Strong Buy | 39 | 82% | $438.34 | -19.2% |
| MRNA | Hold | 31 | 35% | $149.45 | -38.1% |
| REGN | Buy | 37 | 70% | $76.80 | -91.5% |
| NTRA | Strong Buy | 30 | 90% | $142.91 | -60.7% |
| RVMD | Strong Buy | 29 | 93% | $114.11 | -35.8% |